Drug Safety Concerns Could Affect Early Review Stages, FDA's Gottlieb Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The deputy commissioner reiterates that the agency has not become risk averse when it comes to approvals, however.
You may also be interested in...
FDA List Of Potential Safety Signals Has 3 Pfizer Drugs, Echoes Drug Watch Site
FDA's quarterly report that lists potential signals of serious risks for drugs is similar in design to a program that the agency proposed and then withdrew following industry criticism
FDA List Of Potential Safety Signals Has 3 Pfizer Drugs, Echoes Drug Watch Site
FDA's quarterly report that lists potential signals of serious risks for drugs is similar in design to a program that the agency proposed and then withdrew following industry criticism
CDER Abandons “Drug Watch” Program To Communicate Safety In Favor Of Asterisk
FDA issues final guidance describing its approach to communicating drug safety information, including emerging information, to the public.